FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2323813706> ?p ?o ?g. }

• W2323813706 endingPage "647" @default.
• W2323813706 startingPage "645" @default.
• W2323813706 abstract "Bacteraemia caused by non-typhoid Salmonella (NTS) is not an uncommon opportunistic infection in patients with HIV infection and AIDS worldwide. It has been one of the leading aetiologies of the community-acquired bacteraemia of AIDS patients in African countries [1], western countries [2], and Taiwan [3]. NTS bacteraemia in AIDS patients may recur [4,5] and, in fact, recurrent NTS bacteraemia is one of the diagnostic criteria of AIDS [6]. In order to prevent recurrences, prolonged antibacterial prophylaxis with ciprofloxacin, preferably for 6–8 months, has been recommended by the experts [7], the US Public Health Services (USPHS) and the Infectious Disease Society of America (IDSA) [8]. With the introduction of highly active antiretroviral therapy (HAART) and the reconstitution of immunity, the incidences of several major opportunistic diseases decreased significantly [9,10], and primary and secondary prophylaxis against several opportunistic infections, such as Pneumocystis carinii pneumonia [11,12] and disseminated Mycobacterium avium complex infection [13], may be discontinued in patients responding to combination antiretroviral therapy. However, the optimal duration of secondary ciprofloxacin prophylaxis against NTS bacteraemic recurrences had not been investigated by clinical studies despite the USPHS/IDSA recommendations. In this study, we aimed to evaluate whether the duration of secondary prophylaxis with ciprofloxacin against recurrent NTS bacteraemia might be shortened in HIV-infected patients after the start of HAART. A prospective study had been conducted at National Taiwan University Hospital, the largest referral hospital for the management of HIV-related complications in Taiwan, to describe the clinical spectrum and impact of HAART on HIV infection [14]. Since the initiation of HAART, we started to assess the impact of HAART on the recurrence of NTS bacteraemia by the discontinuation of ciprofloxacin as secondary prophylaxis one month after concurrent HAART and ciprofloxacin therapy. From 24 June 1994 to 30 September 2000, 31 out of 461 non-haemophiliac patients (6.7%) with HIV infection developed 38 episodes of NTS bacteraemia: two patients with three episodes, three with two episodes, and 26 with one episode. For patients diagnosed with NTS bacteraemia, ceftriaxone was administered at a dose of 1.0 g every 12 h. for 10–14 days before switching to oral ciprofloxacin at a dose of 500 mg every 12 h as secondary prophylaxis, which was usually continued lifelong at the National Taiwan University Hospital, before the introduction of HAART into Taiwan on 1 April 1997 [14]. Because all of the 31 patients had had a CD4 cell count of less than 200 × 106/l, trimethoprim–sulfamethoxazole was continued for P. carinii pneumonia prophylaxis. Ciprofloxacin was chosen because of good in-vitro activity (90% minimum inhibitory concentration, 0.75 μg/ml) against the Salmonella isolates at this hospital [3]. Consecutive case patients developing NTS bacteraemia between 24 June 1994 and 31 March 1997 (period 1) constituted a historical control group that was compared with the patients between 1 April 1997 and 30 September 2000 (period 2). The patients of period 1 were censored at the time of death or loss to follow-up, or 31 March 1997. Patients surviving beyond 31 March 1997 and enrolled after 1 April 1997 were enrolled into period 2, and were censored at the time of death or loss to follow-up, or 30 September 2000. All of the 31 patients with NTS bacteraemia diagnosed over the past 6 years were at the advanced stage of HIV infection (Centers for Disease Control and Prevention classification C3), with a median CD4 lymphocyte count of 8 × 106/l (range 1–187 × 106/l): 17 being newly diagnosed with HIV infection, and 22 naive to any antiretroviral therapy. NTS bacteraemia was the presenting opportunistic disease of AIDS in 22 patients. The clinical characteristics of the 31 patients with 38 episodes of NTS bacteraemia developing during the two time periods, 23 episodes in period 1 and 15 in period 2, are shown in Table 1. The baseline characteristics of the two cohorts were similar, except that more patients in period 2 were naive to antiretroviral therapy.Table 1: Characteristics of 31 HIV-infected patients with non-typhoid Salmonella bacteraemia in two time periods. During period 1, five out of 16 patients developed recurrent NTS bactaeremia, whereas during period 2, none out of 15 had recurrences (P = 0.043 by Fisher's exact test). The seven episodes of recurrent NTS bacteraemia all occurred during period 1, whereas no recurrence was diagnosed during period 2. The four patients enrolled in period 1 and continued to be observed in period 2 had had no recurrences after the initiation of HAART. The total observation duration of period 1 was 6.94 patient-years and that of period 2 was 15.47 patient-years. Compared with the NTS bacteraemic recurrence rate of 100.86 per 100 patient-years during period 1 [95% confidence interval (CI) 93.53, 108.62], the recurrence rate was zero per 100 patient-years during period 2 (95% CI, 0, 0.2384) (Table 1). The isolates causing recurrent bacteraemia was typed using the method described previously [15], and were shown to be identical in each individual (data not shown). The isolates tested during period 1 did not demonstrate resistance to ciprofloxacin whereas one isolate during period 2 was resistant to ciprofloxacin using the disk susceptibility test. Six patients in period 1 had NTS isolates resistant to trimethoprim–sulfamethoxazole whereas four patients in period 2 had such isolates (P = 0.704). As of 30 September, nine deaths and three losses to follow-up occurred during period 1. The deaths were attributed to lymphoma (two), disseminated M. avium complex infection (two), sepsis of undetermined aetiology (two), cytomegalovirus disease (one), penicilliosis marneffei (one), and aspergillosis (one). Five deaths, but no loss to follow-up, occurred during period 2. The deaths were attributed to acute myocardial infarction (one), concurrent cryptococcosis and penicilliosis marneffei (one), brain tumour of undetermined aetiology (one), pulmonary aspergillosis (one), and Kaposi's sarcoma (one). In earlier reports, recurrences of NTS bacteraemia developed in patients without HAART, despite the fact that they continued prophylactic chemotherapy of good in-vitro activity [4,5]. Our report showed that the risk of recurrent NTS bacteraemia decreased significantly with the introduction of HAART between the two patient cohorts, consisting of similarly immunosuppressed HIV-infected patients in two time periods. The finding of no NTS bacteraemic recurrence after the early discontinuation of ciprofloxacin prophylaxis after the initiation of HAART suggested that the duration of ciprofloxacin prophylaxis, instead of 6 months, might be shortened. However, our study was limited by the fact that it was not a randomized study and the sample size was small. Further randomized control studies are needed to define the optimal duration of secondary ciprofloxacin prophylaxis against NTS bacteraemic recurrences. Chien-Ching Hungab Szu-Min Hsieha Chin-Fu Hsiaoc Mao-Yuan Chena Wang-Hwei Shenga" @default.
• W2323813706 created "2016-06-24" @default.
• W2323813706 creator A5005236574 @default.
• W2323813706 creator A5014114055 @default.
• W2323813706 creator A5049507002 @default.
• W2323813706 creator A5054249064 @default.
• W2323813706 creator A5054470933 @default.
• W2323813706 date "2001-03-01" @default.
• W2323813706 modified "2023-09-26" @default.
• W2323813706 title "Risk of recurrent non-typhoid Salmonella bacteraemia after early discontinuation of ciprofloxacin as secondary prophylaxis in AIDS patients in the era of highly active antiretroviral therapy" @default.
• W2323813706 cites W1625691443 @default.
• W2323813706 cites W1970978424 @default.
• W2323813706 cites W1989041073 @default.
• W2323813706 cites W1997737023 @default.
• W2323813706 cites W2044857933 @default.
• W2323813706 cites W2049623076 @default.
• W2323813706 cites W2063122769 @default.
• W2323813706 cites W2074588097 @default.
• W2323813706 cites W2110799375 @default.
• W2323813706 cites W2318289184 @default.
• W2323813706 cites W2339872299 @default.
• W2323813706 cites W4244970248 @default.
• W2323813706 doi "https://doi.org/10.1097/00002030-200103300-00016" @default.
• W2323813706 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11317004" @default.
• W2323813706 hasPublicationYear "2001" @default.
• W2323813706 type Work @default.
• W2323813706 sameAs 2323813706 @default.
• W2323813706 citedByCount "16" @default.
• W2323813706 countsByYear W23238137062014 @default.
• W2323813706 countsByYear W23238137062015 @default.
• W2323813706 crossrefType "journal-article" @default.
• W2323813706 hasAuthorship W2323813706A5005236574 @default.
• W2323813706 hasAuthorship W2323813706A5014114055 @default.
• W2323813706 hasAuthorship W2323813706A5049507002 @default.
• W2323813706 hasAuthorship W2323813706A5054249064 @default.
• W2323813706 hasAuthorship W2323813706A5054470933 @default.
• W2323813706 hasBestOaLocation W23238137061 @default.
• W2323813706 hasConcept C104317684 @default.
• W2323813706 hasConcept C126322002 @default.
• W2323813706 hasConcept C142462285 @default.
• W2323813706 hasConcept C159047783 @default.
• W2323813706 hasConcept C177713679 @default.
• W2323813706 hasConcept C2776452011 @default.
• W2323813706 hasConcept C2778512257 @default.
• W2323813706 hasConcept C2778715236 @default.
• W2323813706 hasConcept C2779443120 @default.
• W2323813706 hasConcept C2780727368 @default.
• W2323813706 hasConcept C2781065037 @default.
• W2323813706 hasConcept C2993143319 @default.
• W2323813706 hasConcept C2994552716 @default.
• W2323813706 hasConcept C3013748606 @default.
• W2323813706 hasConcept C3019249092 @default.
• W2323813706 hasConcept C501593827 @default.
• W2323813706 hasConcept C520601542 @default.
• W2323813706 hasConcept C523546767 @default.
• W2323813706 hasConcept C54355233 @default.
• W2323813706 hasConcept C547475151 @default.
• W2323813706 hasConcept C55493867 @default.
• W2323813706 hasConcept C71924100 @default.
• W2323813706 hasConcept C86803240 @default.
• W2323813706 hasConcept C89423630 @default.
• W2323813706 hasConceptScore W2323813706C104317684 @default.
• W2323813706 hasConceptScore W2323813706C126322002 @default.
• W2323813706 hasConceptScore W2323813706C142462285 @default.
• W2323813706 hasConceptScore W2323813706C159047783 @default.
• W2323813706 hasConceptScore W2323813706C177713679 @default.
• W2323813706 hasConceptScore W2323813706C2776452011 @default.
• W2323813706 hasConceptScore W2323813706C2778512257 @default.
• W2323813706 hasConceptScore W2323813706C2778715236 @default.
• W2323813706 hasConceptScore W2323813706C2779443120 @default.
• W2323813706 hasConceptScore W2323813706C2780727368 @default.
• W2323813706 hasConceptScore W2323813706C2781065037 @default.
• W2323813706 hasConceptScore W2323813706C2993143319 @default.
• W2323813706 hasConceptScore W2323813706C2994552716 @default.
• W2323813706 hasConceptScore W2323813706C3013748606 @default.
• W2323813706 hasConceptScore W2323813706C3019249092 @default.
• W2323813706 hasConceptScore W2323813706C501593827 @default.
• W2323813706 hasConceptScore W2323813706C520601542 @default.
• W2323813706 hasConceptScore W2323813706C523546767 @default.
• W2323813706 hasConceptScore W2323813706C54355233 @default.
• W2323813706 hasConceptScore W2323813706C547475151 @default.
• W2323813706 hasConceptScore W2323813706C55493867 @default.
• W2323813706 hasConceptScore W2323813706C71924100 @default.
• W2323813706 hasConceptScore W2323813706C86803240 @default.
• W2323813706 hasConceptScore W2323813706C89423630 @default.
• W2323813706 hasIssue "5" @default.
• W2323813706 hasLocation W23238137061 @default.
• W2323813706 hasLocation W23238137062 @default.
• W2323813706 hasOpenAccess W2323813706 @default.
• W2323813706 hasPrimaryLocation W23238137061 @default.
• W2323813706 hasRelatedWork W2018875542 @default.
• W2323813706 hasRelatedWork W2323813706 @default.
• W2323813706 hasRelatedWork W2400245505 @default.
• W2323813706 hasRelatedWork W2463892548 @default.
• W2323813706 hasRelatedWork W2606136660 @default.
• W2323813706 hasRelatedWork W2726204450 @default.
• W2323813706 hasRelatedWork W2782087918 @default.
• W2323813706 hasRelatedWork W3084099822 @default.

• next